Michael Paul Meara retweetledi

Proud to share our work. Important note: GLP-1s and metabolic surgery aren’t competitors—they’re complementary tools along a treatment continuum for a chronic, relapsing disease. The field isn’t shrinking. It’s evolving.
JAMA Surgery@JAMASurgery
Use of #GLP1 receptor agonists surged among patients eligible for metabolic and #BariatricSurgery from 2018 to 2025, while surgery utilization decreased by nearly half, especially for sleeve gastrectomy. ja.ma/4cZXmX0
English



























